CANCER:

Lung Non-Squamous Non-Small Cell Cancer

Related cancers:

‹

Non Small Cell Lung Cancer (2603)

Lung Adenocarcinoma (456)

Lung Non-Small Cell Squamous Cancer (83)

Non Small Cell Lung Cancer (2603)

Lung Adenocarcinoma (456)

Lung Non-Small Cell Squamous Cancer (83)

›

No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval FDA - 2 days (NewA1)	pemetrexed Sensitive: A1 - Approval FDA - 2 days - (New A1)
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval FDA - 2 days (NewA1)	cisplatin + pemetrexed Sensitive: A1 - Approval FDA - 2 days - (New A1)
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval FDA - 2 days (NewA1)	pembrolizumab Sensitive: A1 - Approval FDA - 2 days - (New A1)
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval	cisplatin Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval	bevacizumab + erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	VC Sensitive: A2 - Guideline	VC Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EP Sensitive: A2 - Guideline	EP Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	CaT Sensitive: A2 - Guideline	CaT Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	gefitinib Sensitive: A2 - Guideline	gefitinib Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A2 - Guideline	atezolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	GemVin Sensitive: A2 - Guideline	GemVin Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	GT Sensitive: A2 - Guideline	GT Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	GC Sensitive: A2 - Guideline	GC Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	carboplatin + pemetrexed Sensitive: A2 - Guideline	carboplatin + pemetrexed Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	GemCarbo Sensitive: A2 - Guideline	GemCarbo Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline	carboplatin + docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline	bevacizumab + atezolizumab Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	erlotinib Sensitive: A2 - Guideline	erlotinib Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline	bevacizumab + atezolizumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	afatinib Sensitive: A2 - Guideline	afatinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK fusion ALK fusion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	brigatinib Sensitive: A2 - Guideline	brigatinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK fusion ALK fusion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: A2 - Guideline	alectinib Sensitive: A2 - Guideline
EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline	osimertinib Sensitive: A2 - Guideline
EGFR L858R EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline	osimertinib Sensitive: A2 - Guideline
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline	osimertinib Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: B - Late Trials	osimertinib Sensitive: B - Late Trials
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	camrelizumab Sensitive: B - Late Trials	camrelizumab Sensitive: B - Late Trials
KRAS G12C KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KRAS G12C KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: B - Late Trials	bevacizumab Sensitive: B - Late Trials
ALK positive ALK positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK positive ALK positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: B - Late Trials	bevacizumab Sensitive: B - Late Trials
ALK positive ALK positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK positive ALK positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials	bevacizumab + atezolizumab Sensitive: B - Late Trials
KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials	bevacizumab + atezolizumab Sensitive: B - Late Trials
EGFR L858R EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials	bevacizumab + atezolizumab Sensitive: B - Late Trials
ALK positive ALK positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK positive ALK positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: B - Late Trials	crizotinib Sensitive: B - Late Trials
MHC-II overexpression + PD-L1 negative MHC-II overexpression + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	MHC-II overexpression + PD-L1 negative MHC-II overexpression + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: B - Late Trials	sintilimab Sensitive: B - Late Trials
MHC-II overexpression + PD-L1 underexpression MHC-II overexpression + PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	MHC-II overexpression + PD-L1 underexpression MHC-II overexpression + PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: B - Late Trials	sintilimab Sensitive: B - Late Trials
ALK rearrangement ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ceritinib Sensitive: B - Late Trials	ceritinib Sensitive: B - Late Trials
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials
EGFR wild-type + MET overexpression EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type + MET overexpression EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: B - Late Trials	ABBV-399 Sensitive: B - Late Trials
ALK positive ALK positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK positive ALK positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ensartinib Sensitive: C1 - Off-label	ensartinib Sensitive: C1 - Off-label
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C2 – Inclusion Criteria	erlotinib + ABBV-399 Sensitive: C2 – Inclusion Criteria
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + afatinib Sensitive: C2 – Inclusion Criteria	bevacizumab + afatinib Sensitive: C2 – Inclusion Criteria
MET overexpression MET overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	MET overexpression MET overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: C2 – Inclusion Criteria	ABBV-399 Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	binimetinib Sensitive: C2 – Inclusion Criteria	binimetinib Sensitive: C2 – Inclusion Criteria
ALK rearrangement ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria	crizotinib Sensitive: C2 – Inclusion Criteria
ROS1 rearrangement ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ROS1 rearrangement ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria	crizotinib Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR T790M EGFR T790M	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials	PD-L1 inhibitor Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials	docetaxel Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials	docetaxel Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials	atezolizumab Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials	atezolizumab Resistant: C3 – Early Trials
EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR inhibitor Sensitive: C3 – Early Trials	EGFR inhibitor Sensitive: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials	camrelizumab + rivoceranib Sensitive: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials	camrelizumab + rivoceranib Sensitive: C3 – Early Trials
STK11 mutation + KEAP1 mutation STK11 mutation + KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation + KEAP1 mutation STK11 mutation + KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials	camrelizumab + rivoceranib Sensitive: C3 – Early Trials
MET positive MET positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	MET positive MET positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials	erlotinib + ABBV-399 Sensitive: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	durvalumab + CP-675206 Resistant: C3 – Early Trials	durvalumab + CP-675206 Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	durvalumab Resistant: C3 – Early Trials	durvalumab Resistant: C3 – Early Trials
EGFR expression EGFR expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR expression EGFR expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
CEACAM5 overexpression CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: C3 – Early Trials	SAR408701 Sensitive: C3 – Early Trials
MGAM mutation MGAM mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	MGAM mutation MGAM mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
NRAS mutation NRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	NRAS mutation NRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	binimetinib Sensitive: C3 – Early Trials	binimetinib Sensitive: C3 – Early Trials
MAP2K1 mutation MAP2K1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	MAP2K1 mutation MAP2K1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	binimetinib Sensitive: C3 – Early Trials	binimetinib Sensitive: C3 – Early Trials
NKX2-1 expression + PD-L1 expression NKX2-1 expression + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	NKX2-1 expression + PD-L1 expression NKX2-1 expression + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression + KRAS mutation PD-L1 overexpression + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression + KRAS mutation PD-L1 overexpression + KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + abemaciclib Sensitive: C3 – Early Trials	pembrolizumab + abemaciclib Sensitive: C3 – Early Trials
KRAS G12V KRAS G12V	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	KRAS G12V KRAS G12V	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: C3 – Early Trials	sintilimab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials	bevacizumab + atezolizumab Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR wild-type EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	tislelizumab Sensitive: C3 – Early Trials	tislelizumab Sensitive: C3 – Early Trials
ALK wild-type ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	tislelizumab Sensitive: C3 – Early Trials	tislelizumab Sensitive: C3 – Early Trials

Lung Non-Squamous Non-Small Cell Cancer

Associations(86)

Associations
(86)